Fractyl Health, Inc. (GUTS)

Market Cap	99.08M
Revenue (ttm)	97,000
Net Income (ttm)	-68.97M
Shares Out	48.10M
EPS (ttm)	-2.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	292,609
Open	2.200
Previous Close	2.190
Day's Range	2.020 - 2.225
52-Week Range	1.740 - 14.500
Beta	n/a
Analysts	Buy
Price Target	18.00 (+773.79%)
Earnings Date	Nov 12, 2024

About GUTS

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably alteri...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 2, 2024
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: GUTS
• Website: https://fractyl.com

Analyst Forecast

According to 2 analysts, the average rating for GUTS stock is "Buy." The 12-month stock price forecast is $18.0, which is an increase of 773.79% from the latest price.

Price Target

$18.0

(773.79% upside)

Analyst Consensus: Buy